Literature DB >> 6871073

Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris.

H L Fung, J O Parker.   

Abstract

The plasma concentration of isosorbide dinitrate (ISDN) was monitored up to 24 h after a chronic oral dose of 60 mg in six patients with coronary artery disease. A terminal half-life of 7.7 +/- 2.6 h (mean +/- s.d.) was observed. The presence of this prolonged disappearance phase provided at least a partial explanation for the observed accumulation of ISDN in plasma after chronic dosing on a six hourly regimen.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6871073      PMCID： PMC1427931          DOI： 10.1111/j.1365-2125.1983.tb01560.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  4 in total

1.  Kinetics of isosorbide dinitrate and relationships to pharmacological effects.

Authors:  H L Fung; E F McNiff; D Ruggirello; A Darke; U Thadani; J O Parker
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

2.  Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies.

Authors:  H Laufen; F Scharpf; G Bartsch
Journal:  J Chromatogr       Date:  1978-11-01

3.  Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.

Authors:  T Taylor; L F Chasseaud; E Doyle; A Darragh; D A O'Kelly; D Fitzgerald
Journal:  Biopharm Drug Dispos       Date:  1980 Jan-Mar       Impact factor: 1.627

4.  Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953
  4 in total
  3 in total

1.  Influence of exercise on plasma concentrations of isosorbide dinitrate.

Authors:  M G Bogaert; R A Lefebvre; M T Rosseel; J Bouckaert
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.

Authors:  W Schneider; G Menke; R Heidemann; P Satter; M Kaltenbach; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann; G Neugebauer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.